Sanofi (NASDAQ:SNY) Stock Rating Upgraded by Wall Street Zen

Sanofi (NASDAQ:SNY) was upgraded by research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a report issued on Saturday.

A number of other brokerages also recently weighed in on SNY. BNP Paribas initiated coverage on Sanofi in a report on Tuesday, April 15th. They issued an “outperform” rating and a $65.00 target price for the company. Barclays reaffirmed an “overweight” rating on shares of Sanofi in a research report on Wednesday, July 2nd. Morgan Stanley set a $56.00 target price on Sanofi in a research report on Monday, June 2nd. Hsbc Global Res raised Sanofi to a “strong-buy” rating in a research report on Monday, April 28th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Sanofi in a research report on Tuesday, June 3rd. Two equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and three have assigned a strong buy rating to the company. According to data from MarketBeat, Sanofi presently has a consensus rating of “Buy” and an average target price of $62.00.

Sanofi Price Performance

Sanofi stock opened at $46.75 on Friday. The stock’s 50 day moving average is $49.10 and its 200 day moving average is $52.11. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The firm has a market cap of $114.80 billion, a P/E ratio of 11.24, a P/E/G ratio of 1.12 and a beta of 0.48. Sanofi has a one year low of $44.73 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, July 31st. The company reported $0.90 EPS for the quarter, missing analysts’ consensus estimates of $0.96 by ($0.06). The company had revenue of $11.34 billion during the quarter, compared to analyst estimates of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%. Sanofi’s revenue was down 7.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.73 earnings per share. As a group, research analysts expect that Sanofi will post 4.36 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in SNY. Ameritas Advisory Services LLC purchased a new stake in Sanofi during the 2nd quarter worth about $28,000. Accent Capital Management LLC purchased a new stake in Sanofi during the 1st quarter worth about $29,000. Eastern Bank lifted its holdings in Sanofi by 121.0% during the 1st quarter. Eastern Bank now owns 548 shares of the company’s stock worth $30,000 after purchasing an additional 300 shares in the last quarter. Bessemer Group Inc. lifted its holdings in Sanofi by 59.8% during the 4th quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock worth $32,000 after purchasing an additional 242 shares in the last quarter. Finally, Banque Transatlantique SA purchased a new stake in Sanofi during the 1st quarter worth about $33,000. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.